Viatris Inc.

15.73-0.0600-0.38%Vol 4.13M1Y Perf 1.00%
Jun 11th, 2021 16:00 DELAYED
BID15.72 ASK15.73
Open15.76 Previous Close15.79
Pre-Market- After-Market-
 - -  - -%
Target Price
18.64 
Analyst Rating
— — 0.00
Potential %
18.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     46.33
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     38.14
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★+     48.47
Market Cap19.01B 
Earnings Rating
Price Range Ratio 52W %
47.13 
Earnings Date
5th Aug 2021

Today's Price Range

15.6315.79

52W Range

12.9418.86

5 Year PE Ratio Range

20.20770.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
2.21%
1 Month
0.06%
3 Months
9.54%
6 Months
-
1 Year
1.00%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
VTRS15.73-0.0600-0.38
AAPL127.351.24000.98
GOOG2 513.93-7.6700-0.30
MSFT257.890.65000.25
XOM62.17-0.5800-0.92
WFC45.680.59001.31
JNJ164.96-2.1200-1.27
FB331.26-1.2000-0.36
GE13.690.06000.44
JPM160.29-0.1100-0.07
Financial StrengthValueIndustryS&P 500US Markets
0.60
1.20
0.51
1.16
-1.20
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
57.70
-4.70
18.70
-3.10
-12.69
RevenueValueIndustryS&P 500US Markets
13.76B
11.38
1.95
3.33
Earnings HistoryEstimateReportedSurprise %
Q01 20210.790.9216.46
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th Aug 2021
Estimated EPS Next Report0.89
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume4.13M
Shares Outstanding1.21B
Trades Count23.46K
Dollar Volume262.30M
Avg. Volume10.48M
Avg. Weekly Volume5.24M
Avg. Monthly Volume7.56M
Avg. Quarterly Volume9.37M

Viatris Inc. (NASDAQ: VTRS) stock closed at 15.73 per share at the end of the most recent trading day (a -0.38% change compared to the prior day closing price) with a volume of 4.14M shares and market capitalization of 19.01B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 35000 people. Viatris Inc. CEO is Michael Goettler.

The one-year performance of Viatris Inc. stock is 1%, while year-to-date (YTD) performance is %. VTRS stock has a five-year performance of %. Its 52-week range is between 12.94 and 18.86, which gives VTRS stock a 52-week price range ratio of 47.13%

Viatris Inc. currently has a PE ratio of -7.70, a price-to-book (PB) ratio of 0.87, a price-to-sale (PS) ratio of 1.35, a price to cashflow ratio of 6.70, a PEG ratio of 2.32, a ROA of -3.80%, a ROC of -3.98% and a ROE of -10.35%. The company’s profit margin is -12.69%, its EBITDA margin is 18.70%, and its revenue ttm is $13.76 Billion , which makes it $11.38 revenue per share.

Of the last four earnings reports from Viatris Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.89 for the next earnings report. Viatris Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Viatris Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Viatris Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Viatris Inc. has a dividend yield of 2.86% with a dividend per share of $0.44 and a payout ratio of -%.

Viatris Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 46.64, ATR14 : 0.32, CCI20 : 66.81, Chaikin Money Flow : -0.03, MACD : 0.28, Money Flow Index : 62.03, ROC : 5.01, RSI : 61.77, STOCH (14,3) : 81.90, STOCH RSI : 0.76, UO : 59.54, Williams %R : -18.10), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Viatris Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Viatris Inc.

The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front.

CEO: Michael Goettler

Telephone: +1 724 514-1800

Address: 1000 Mylan Boulevard, Canonsburg 15317, PA, US

Number of employees: 35 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

70%30%

Bearish Bullish

73%27%

News

Stocktwits